Bobby Gaspar is a physician/scientist working in paediatric immunology
at the Institute of Child Health (ICH) and Great Ormond Street London, as
well as co-founder and chief Executive Officer at Orchard Therapeutics, a
biotechnology company arising from his work at UCL/GOSH that is making gene
therapy medicines for severe genetic diseases. He initially trained in paediatrics
and then became interested in primary immunodeficiencies. His interests are
in many different aspects of primary immunodeficiency including understanding the molecular and
cellular defects and disease pathogenesis, bone marrow transplantation for severe immunodeficiencies
and the development of gene and cell therapy for these conditions. Over the last decade, his team
have conducted clinical trials that have shown that their approach to gene therapy can potentially
permanently correct the immune defect in specific immunodeficiency conditions.